ConductScience.org, home

Paper42136397

Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial.

Chang VWL and 11 others. Clin Infect Dis, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial. Papers, record 42136397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42136397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial.
PubMed
Journal
Clin Infect Dis
PubMed
Year
2026
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Multicenter Study
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-10-09
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chang VWLVicky W Lhttps://orcid.org/0000-0002-4880-9082
2Li QQingbinhttps://orcid.org/0009-0003-7882-1319
3Barnes DDavid
4Byrne ALAnthony Lhttps://orcid.org/0000-0003-3192-0726
5Cho JGJin-Gunhttps://orcid.org/0000-0002-0735-4691
6Foo SSooWeihttps://orcid.org/0009-0008-8763-4298
7Goldberg HHazel
8Gray TTimothyhttps://orcid.org/0000-0002-2591-0284
9Harrington ZZintahttps://orcid.org/0000-0002-8104-5598
10Rofail LMLydia Mhttps://orcid.org/0009-0009-4244-9125
11Ulbricht EEvan
12Fox GJGregory J

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
RifampinMajor topic
IsoniazidMajor topic
Antitubercular AgentsMajor topic
TuberculosisMajor topic
Humans
Female
Male
Adult
Middle Aged
Australia
Treatment Outcome
Drug Administration Schedule
Drug Therapy, Combination

Source PubMed

Download CSV of topics

References14

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125904367
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Clin Infect Dis2015https://conductscience.org/library/papers/25904367PubMed
227522233The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.Lancet Infect Dis2016https://conductscience.org/library/papers/27522233PubMed
320091503Treatment of latent tuberculosis infection in HIV infected persons.Cochrane Database Syst Rev2010https://conductscience.org/library/papers/20091503PubMed
411069825Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk.Am J Respir Crit Care Med2000https://conductscience.org/library/papers/11069825PubMed
529224209SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.Intern Med J2017https://conductscience.org/library/papers/29224209PubMed
630865794One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.N Engl J Med2019https://conductscience.org/library/papers/30865794PubMed
730067931Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.N Engl J Med2018https://conductscience.org/library/papers/30067931PubMed
825580725Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.JAMA Pediatr2015https://conductscience.org/library/papers/25580725PubMed
921732833New regimens to prevent tuberculosis in adults with HIV infection.N Engl J Med2011https://conductscience.org/library/papers/21732833PubMed
1022150035Three months of rifapentine and isoniazid for latent tuberculosis infection.N Engl J Med2011https://conductscience.org/library/papers/22150035PubMed
1130067928Safety and Side Effects of Rifampin versus Isoniazid in Children.N Engl J Med2018https://conductscience.org/library/papers/30067928PubMed
1225111745Treatment of latent tuberculosis infection: a network meta-analysis.Ann Intern Med2014https://conductscience.org/library/papers/25111745PubMed
1336966788Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.Lancet Respir Med2023https://conductscience.org/library/papers/36966788PubMed
1427243774Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.AIDS2016https://conductscience.org/library/papers/27243774PubMed

Download CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42136397

GET https://conductscience.org/api/papers/v1/42136397/authors